Primary γδ Cell Clones Can Be Defined Phenotypically and Functionally as Th1/Th2 Cells and Illustrate the Association of CD4 with Th2 Differentiation
A. Hayday , Li Wen , M. J. Owen , D. F. Barber
Journal of Immunology 160 ( 4) 1965 -1974
106
1998
Erratum: BAC Consensus Conference, November 4-6, 2004: Epidemiology, pathogenesis, and preclinical models (Journal of Thoracic Oncology (2006) 1, (S2-S7))
D. C. Christiani , A. M. Malkinson , K. K. Wong , J. C. DeMartini
Journal of Thoracic Oncology 2 ( 1)
4
2007
Influence of site of expression on the fetal gamma delta T-cell receptor repertoire.
S. Kyes , W. Pao , A. Hayday
Proceedings of the National Academy of Sciences of the United States of America 88 ( 17) 7830 -7833
18
1991
KRAS mutations in non-small cell lung cancer.
G. J. Riely , J. Marks , W. Pao
Proceedings of the American Thoracic Society 6 ( 2) 201 -205
667
2009
Use of avian retroviral vectors to introduce transcriptional regulators into mammalian cells for analyses of tumor maintenance
W. Pao , D. S. Klimstra , G. H. Fisher , H. E. Varmus
Proceedings of the National Academy of Sciences of the United States of America 100 ( 15) 8764 -8769
58
2003
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1
K. Ohashi , L. V. Sequist , M. E. Arcila , T. Moran
Proceedings of the National Academy of Sciences of the United States of America 109 ( 31) 12282 -12283
481
2012
Phase II study of gefitinib treatment in advanced thymic malignancies
A. Kurup , M. Burns , S. Dropcho , W. Pao
Journal of Clinical Oncology 23 7068 -7068
68
2005
Phase I/II trial of gefitinib and RAD001 (everolimus) in patients (pts) with advanced non-small cell lung cancer (NSCLC)
D. T. Milton , M. G. Kris , C. G. Azzoli , J. E. Gomez
Journal of Clinical Oncology 23 7104 -7104
25
2005
Mechanism for activation of mutated epidermal growth factor receptors in lung cancer.
M. Red Brewer , C.-H. Yun , D. Lai , M. A. Lemmon
Proceedings of the National Academy of Sciences of the United States of America 110 ( 38) 201220050
84
2013
Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase
J. T. Garrett , M. G. Olivares , C. Rinehart , N. D. Granja-Ingram
Proceedings of the National Academy of Sciences of the United States of America 108 ( 12) 5021 -5026
482
2011
Disruption of epithelial gamma delta T cell repertoires by mutation of the Syk tyrosine kinase.
C. A. Mallick-Wood , W. Pao , A. M. Cheng , J. M. Lewis
Proceedings of the National Academy of Sciences of the United States of America 93 ( 18) 9704 -9709
61
1996
Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma
N. Girard , C. S. Sima , D. M. Jackman , L. V. Sequist
European Respiratory Journal 39 ( 2) 366 -372
79
2012
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases
T. A. Carter , L. M. Wodicka , N. P. Shah , A. M. Velasco
Proceedings of the National Academy of Sciences of the United States of America 102 ( 31) 11011 -11016
543
2005
From academia to industry: a road more travelled.
W. Pao
Annals of Oncology 28 ( 9) 2312 -2314
1
2017
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
W. Pao , V. Miller , M. Zakowski , J. Doherty
Proceedings of the National Academy of Sciences of the United States of America 101 ( 36) 13306 -13311
5,203
2004
EGFR mutation and copy number, EGFR protein expression and KRAS mutation as predictors of outcome with erlotinib in bronchioloalveolar cell carcinoma (BAC): Results of a prospective phase II trial.
V. A. Miller , M. Zakowski , G. J. Riely , W. Pao
Journal of Clinical Oncology 24 7003 -7003
40
2006
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer
M. L. Sos , S. Fischer , R. Ullrich , M. Peifer
Proceedings of the National Academy of Sciences of the United States of America 106 ( 43) 18351 -18356
285
2009
Predicting Sensitivity of Non–Small-Cell Lung Cancer to Gefitinib: Is There a Role for P-Akt?
W. Pao , V. A. Miller , E. Venkatraman , M. G. Kris
Journal of the National Cancer Institute 96 ( 15) 1117 -1119
29
2004
Translating genomic information into clinical medicine: Lung cancer as a paradigm
M. A. Levy , C. M. Lovly , W. Pao
Genome Research 22 ( 11) 2101 -2108
60
2012
Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance.
P. Jia , H. Jin , C. B. Meador , J. Xia
Genome Research 23 ( 9) 1434 -1445
61
2013